Your browser doesn't support javascript.
loading
Glycogen as an advantageous polymer carrier in cancer theranostics: Straightforward in vivo evidence.
Gálisová, Andrea; Jirátová, Markéta; Rabyk, Mariia; Sticová, Eva; Hájek, Milan; Hrubý, Martin; Jirák, Daniel.
Afiliação
  • Gálisová A; MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Jirátová M; MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Rabyk M; Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic.
  • Sticová E; Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
  • Hájek M; Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Hrubý M; Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Jirák D; MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Sci Rep ; 10(1): 10411, 2020 06 26.
Article em En | MEDLINE | ID: mdl-32591567
ABSTRACT
As a natural polysaccharide polymer, glycogen possesses suitable properties for use as a nanoparticle carrier in cancer theranostics. Not only it is inherently biocompatible, it can also be easily chemically modified with various moieties. Synthetic glycogen conjugates can passively accumulate in tumours due to enhanced permeability of tumour vessels and limited lymphatic drainage (the EPR effect). For this study, we developed and examined a glycogen-based carrier containing a gadolinium chelate and near-infrared fluorescent dye. Our aim was to monitor biodistribution and accumulation in tumour-bearing rats using magnetic resonance and fluorescence imaging. Our data clearly show that these conjugates possess suitable imaging and tumour-targeting properties, and are safe under both in vitro and in vivo conditions. Additional modification of glycogen polymers with poly(2-alkyl-2-oxazolines) led to a reduction in the elimination rate and lower uptake in internal organs (lower whole-body

background:

45% and 27% lower MRI signals of oxazoline-based conjugates in the liver and kidneys, respectively compared to the unmodified version). Our results highlight the potential of multimodal glycogen-based nanopolymers as a carrier for drug delivery systems in tumour diagnosis and treatment.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Nanomedicina Teranóstica / Glicogênio / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Nanomedicina Teranóstica / Glicogênio / Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article